KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Interest & Investment Income (2018 - 2025)

Historic Interest & Investment Income for Aurinia Pharmaceuticals (AUPH) over the last 7 years, with Q3 2025 value amounting to $3.3 million.

  • Aurinia Pharmaceuticals' Interest & Investment Income fell 2228.73% to $3.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.1 million, marking a year-over-year decrease of 1986.89%. This contributed to the annual value of $17.0 million for FY2024, which is 15.89% down from last year.
  • According to the latest figures from Q3 2025, Aurinia Pharmaceuticals' Interest & Investment Income is $3.3 million, which was down 2228.73% from $3.2 million recorded in Q2 2025.
  • In the past 5 years, Aurinia Pharmaceuticals' Interest & Investment Income registered a high of $4.6 million during Q4 2023, and its lowest value of $106000.0 during Q3 2021.
  • In the last 5 years, Aurinia Pharmaceuticals' Interest & Investment Income had a median value of $3.3 million in 2025 and averaged $2.6 million.
  • As far as peak fluctuations go, Aurinia Pharmaceuticals' Interest & Investment Income skyrocketed by 256880.73% in 2022, and later tumbled by 2384.82% in 2025.
  • Aurinia Pharmaceuticals' Interest & Investment Income (Quarter) stood at $109000.0 in 2021, then surged by 2568.81% to $2.9 million in 2022, then skyrocketed by 57.03% to $4.6 million in 2023, then dropped by 12.7% to $4.0 million in 2024, then decreased by 16.85% to $3.3 million in 2025.
  • Its last three reported values are $3.3 million in Q3 2025, $3.2 million for Q2 2025, and $3.6 million during Q1 2025.